Table 1.
Patient treatment and timeline of chronic BCG-osis at NIH
| Age (y) | Culture site | Smear | Culture | Imaging-brain | Imaging-lung | Antibiotics | Cytokine adjuvants |
|---|---|---|---|---|---|---|---|
| 3 | Scalp | Many | Positive | Multiple enhancing lesions | Pleural mass | Clari, INH, RIF | None |
| 3 | Lung | Many | Positive | Multiple enhancing lesions | Pleural mass | Clari, INH, RIF | None |
| 3.2 | Scalp | Negative | Positive | Stable | Stable | Clari, INH, RIF, ETH, AMI, Levo | IFNγ |
| 3.3 | Scalp | Few | Negative | Stable | Increased size | Azi, INH, RIF, ETH,AMI | IFNγ |
| 3.3 | Lung | Moderate | Liquid media only | Stable | Increased size | Azi, INH, RIF, ETH,AMI | IFNγ |
| 3.7 | Scalp | Negative | Negative | Stable | Increased size | Azi, INH, ETH, Levo, LZD, Clofaz, Capreo | IFNγ and IFNα |
| 3.8 | Scalp | Negative | Negative | Stable | Stable | Azi, INH, ETH, Levo, LZD, Clofaz, Capreo | IFNγ and IFNα |
| 4.0 | Lung | Negative | Negative | Stable | Increased size | Azi, INH, ETH, Levo, LZD, Clofaz | IFNγ and IFNα |
Clari, clarithromycin; INH, isoniazid; RIF, rifampin; ETH, ethambutol; AMI, amikacin; Levo, levofloxacin; Azi, azithromycin; LZD, linezolid; Clofaz, clofazimine; Capreo, capreomycin.